Voss Capital LP lessened its holdings in shares of Kura Oncology, Inc. (NASDAQ:KURA – Free Report) by 90.3% during the 4th quarter, Holdings Channel reports. The firm owned 29,737 shares of the company’s stock after selling 275,922 shares during the period. Voss Capital LP’s holdings in Kura Oncology were worth $309,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. IFP Advisors Inc raised its stake in Kura Oncology by 115.3% during the 4th quarter. IFP Advisors Inc now owns 2,398 shares of the company’s stock valued at $25,000 after purchasing an additional 1,284 shares during the period. EverSource Wealth Advisors LLC raised its stake in Kura Oncology by 392.8% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 3,854 shares of the company’s stock valued at $34,000 after purchasing an additional 3,072 shares during the period. Allworth Financial LP raised its stake in Kura Oncology by 59.9% during the 4th quarter. Allworth Financial LP now owns 4,146 shares of the company’s stock valued at $43,000 after purchasing an additional 1,553 shares during the period. PNC Financial Services Group Inc. raised its stake in Kura Oncology by 127.2% during the 3rd quarter. PNC Financial Services Group Inc. now owns 6,732 shares of the company’s stock valued at $60,000 after purchasing an additional 3,769 shares during the period. Finally, Tower Research Capital LLC TRC raised its stake in Kura Oncology by 471.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 12,071 shares of the company’s stock valued at $70,000 after purchasing an additional 9,958 shares during the period.
Wall Street Analysts Forecast Growth
Several analysts recently issued reports on KURA shares. Zacks Research raised Kura Oncology from a “strong sell” rating to a “hold” rating in a research note on Thursday, February 26th. Wells Fargo & Company set a $24.00 target price on Kura Oncology in a research note on Thursday, June 4th. Lake Street Capital started coverage on Kura Oncology in a report on Tuesday, April 14th. They set a “buy” rating and a $23.00 price target for the company. Cantor Fitzgerald restated an “overweight” rating on shares of Kura Oncology in a report on Thursday, June 4th. Finally, Oppenheimer set a $24.00 price target on Kura Oncology in a report on Thursday, May 28th. Ten research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $25.58.
Kura Oncology Stock Performance
NASDAQ KURA opened at $9.05 on Friday. The stock has a market capitalization of $803.37 million, a PE ratio of -2.70 and a beta of 0.36. The business has a 50 day simple moving average of $9.31 and a two-hundred day simple moving average of $9.33. The company has a debt-to-equity ratio of 0.09, a current ratio of 6.15 and a quick ratio of 6.14. Kura Oncology, Inc. has a 1-year low of $5.45 and a 1-year high of $12.49.
Kura Oncology (NASDAQ:KURA – Get Free Report) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.83) earnings per share for the quarter, beating the consensus estimate of ($0.88) by $0.05. The business had revenue of $18.27 million during the quarter, compared to analysts’ expectations of $25.97 million. Kura Oncology had a negative return on equity of 141.95% and a negative net margin of 411.19%. On average, research analysts predict that Kura Oncology, Inc. will post -3.47 EPS for the current fiscal year.
About Kura Oncology
Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.
The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.
Featured Articles
- Five stocks we like better than Kura Oncology
- TJX: Retail’s Apex Predator Feasts on Inflation
- MarketBeat Week in Review – 06/08 – 06/12
- SpaceX Rings the Bell and Shatters Every Record
- Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story?
Want to see what other hedge funds are holding KURA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kura Oncology, Inc. (NASDAQ:KURA – Free Report).
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
